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Abstract:  
Introduction: Associations of endogenous sex hormone levels and all as well as  estrogen-receptor 
(ER)-positive breast cancers are well described. However, studies investigating their association with 
ER-negative tumours are limited and none use accurate assays such as mass spectrometry. 
Methods: Within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), a nested case-
control study was undertaken of postmenopausal-women who developed ER-negative (n=92) or  ER-
positive (n=205) breast cancer after sample donation and 297 (1:1) age-matched controls. Androgens 
(testosterone and androstenedione) were measured using mass spectrometry and estradiol by 
extraction radioimmunoassay (RIA). Bioavailable estradiol and testosterone were calculated using the 
total hormone level and the sex hormone-binding globulin concentration. Subjects were classified 
according to the quartile range among controls. Logistic regression was used to estimate odds-
ratio(OR) and 95%confidence-intervals(CI) of the associations between two factors and breast cancer 
risk. A separate analysis was done by stratifying the women based on whether they provided their 
samples less than or more than 2 years before diagnosis.  
Results: Estradiol and free estradiol were significantly higher prior to diagnosis of ER-negative breast 
cancer compared with controls while androgens and SHBG did not show any difference. Estradiol, free 
estradiol, free testosterone and SHBG were significantly higher before ER-positive breast cancer 
diagnosis compared with controls. Women had a twofold increased ER-negative breast cancer risk if 
estradiol and free estradiol were in the top quartile but not androgens (testosterone and 
androstenedione) or SHBG. These associations remained significant only when samples closer (median 
1.1y before) to diagnosis were analysed rather than farther from diagnosis (median 2.9y before). 
Women had a 2.34 (95% CI: 1.21-4.61, p=0.001), 2.21 (95% CI: 1.14-4.38, p=0.001), 2 (95% CI: 1.05-
3.89, p=0.005) fold increased ER-positive breast cancer risk if estradiol, free estradiol and free 
testosterone respectively were in the top quartile. These associations remained significant regardless 
of whether the samples were collected less than or more than 2 years prior to diagnosis.  
Conclusion: In postmenopausal women increased estrogens but not androgens are associated with 
ER-negative breast cancer. Previously reported associations of estradiol and free testosterone with 
ER-positive breast cancer are confirmed. The use of mass spectrometry and sensitive RIA add validity 
to these findings.  
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Introduction 
Breast cancer remains one of the leading causes of cancer death among women despite the huge 
progress that has been made in treatment (1, 2). It is a complex and heterogeneous disease with 
multiple histopathological and molecular subtypes which have varying clinical outcome (3). Currently, 
estrogen (ER), progesterone (PR) and herceptin-2 (HER2) receptor (4) status in the tumour is used to 
guide breast cancer treatment and provide prognostic information.  
A key aspect of trying to improve disease outcome has been identification of risk factors (5). Many of 
these, such as early menarche and late menopause (6), mediate their effect through a hormonal 
mechanism (7). This has led to the investigation of associations of endogenous sex hormone levels 
and breast cancer risk (8-12). The majority of such studies have explored overall breast cancer (8, 10, 
11) or ER-positive breast cancer risk (9, 12). There are only five studies that have reported the 
association by hormone receptor status (13-17). They are characterised by relatively small numbers 
and conflicting results.  
Additional issues are the assays used to measure sex steroid hormones. The most commonly used 
methods are direct immunoassays, which tend to overestimate concentrations and suffer from cross-
reactivity with other steroids (18).  In the last few years, assays with an organic extraction step and 
mass spectrometry are emerging as the ‘gold standard’ (19). Mass spectrometry has improved 
specificity and has a wide analytical range compared to the immunoassays and allows the 
measurement of multiple hormones during a single run (20). There are two published studies that we 
are aware of which have used mass spectrometry to examine the association of sex steroid hormones 
and breast cancer risk and this was limited to estrogens (21, 22). There is growing consensus of the 
need for more studies evaluating breast cancer risk by hormone receptor status (4) using more 
accurate hormone assays. 
We have previously shown the relationship between postmenopausal sex steroid hormone levels with 
hormone receptor positive breast cancer risk using immunoassays in the UK Collaborative Trial of 
Ovarian Cancer Risk (UKCTOCS) (9). The current analysis expands this nested case-control study to 
include ER-negative cases with androgens measured using mass spectrometry and the estrogens using 
sensitive and specific extraction radioimmunoassay.  
 
Methods 
UKCTOCS is a multicentre randomized controlled trial of ovarian cancer screening. The trial design has 
been previously described (23). In brief, women aged 50–74 were recruited from England, Northern 
Ireland and Wales through random invitation from age/sex registers of participating Primary Care 
Trusts. At recruitment, each woman donated a blood sample, filled in a baseline questionnaire, and 
provided written consent giving permission to access their medical records and use of their 
data/samples in future studies (9, 23). All participants continue to be followed up through a ‘flagging 
study’ with the National Health System Information Centre for Health and Social Care who provide 
data on cancer registrations and deaths.  
The UKCTOCS was approved by the UK North West Multicentre Research Ethics Committees (North 
West MREC 00/8/34). Ethical approval for this nested case–control study was obtained from the Joint 
UCL/UCLH Committees on the Ethics of Human Research (22nd February 2007, 06/Q0505/102). 
 
Subjects 
The treating physician of women diagnosed with breast cancer during the trial were sent a 
questionnaire requesting information regarding their diagnosis (histology), hormone receptor status 
and treatment (24). From those in whom complete data were available, women who developed ER-
positive or ER-negative invasive breast cancer after joining UKCTOCS, were not on hormone replace 
therapy treatment at recruitment and had donated a serum sample between 6 months and 5 years 
before diagnosis were chosen as ‘cases’. Controls were women who were not on HRT at recruitment 
and had no history of cancer at last follow-up. Each breast cancer case was age matched (+/- 5 years) 
to one control woman who had donated serum samples on the same day and in the same clinic.  
 
Serum processing 
All blood samples were collected into Greiner Bio one gel tubes (Cat no: 455071) at the participating 
centers, shipped overnight to the central laboratory and centrifuged at 2000 g for 10 min. The serum 
was removed from the cells within 56 h of sample collection and was frozen using a two-stage freezing 
process: 12 h at −80 °C and then placed in liquid nitrogen (vapor phase) at −180 °C. A novel semi-
automated system aliquoted serum in 500 μl straws that were heat sealed, bar coded, data based, and 
stored in liquid nitrogen tanks. The samples were only thawed once, at the time of the assay. 
 
Measurement of hormone levels  
Estradiol by extraction radioimmunoassay 
Unconjugated estradiol was measured in 100 uL of sample in duplicate using an in-house 
radioimmunoassay (25).  Estradiol was extracted into 1 mL diethyl ether (Vickers) by vortex mixing for 
3 min (after addition of 10 uL 2M sodium hydroxide). After freezing the aqueous layer in a dry-ice 
methanol bath, the organic layer was decanted into a glass tube. Solvent was removed by vacuum 
oven. Competitive radioimmunoassay was performed on the dried extract using an antiserum raised 
in a goat against estradiol-6-BSA conjugate and iodinated estradiol label (125I, Siemens). Unbound 
estradiol was adsorbed onto dextran-coated charcoal, leaving the bound fraction in solution. The 
bound fraction was decanted and counted in the gamma counter (Wallac Wizard). The estradiol values 
for quality control material and study samples were obtained by interpolation of the counts bound 
using a standard curve of estradiol concentrations from 5-1000 pmol/L by Multicalc software. 
Significant cross-reactions are seen with Estrone (10%) and Estriol (1.3%). Inter-assay imprecision of 
estradiol in quality control material is shown in Supplementary table 1.  
 
Testosterone and androstenedione by tandem mass spectrometry 
Testosterone and androstenedione were measured in 100 uL sample using tandem mass spectrometry 
(LC-MS/MS). Tri-deuterated (d3) testosterone and hepta-deuterated (d7) androstenedione were used 
as the internal standards.  The steroids were extracted into 1 mL of tert-butyl methyl ether (MTBE, 
Fisher) by vortex mixing for 5 min.  After freezing the aqueous layer in a dry-ice methanol bath, the 
organic layer was decanted into a glass tube (10 x 75 mm).  Solvent was removed using a vacuum oven 
at 40oC. The dried residue was reconstituted in 200 uL of aqueous methanol (1:1 solution by volume, 
Fisher) and mixed thoroughly.  The extracts were transferred to a deep well micro-titre plate (Fisher), 
which was then sealed with film.Extract (30 uL) was injected onto the LC column (Sunfire 2.5 uM C18 
50 x 4.6 mm, Waters).  The LC-MS/MS system consisted of a Shimadzu Prominence LC (LC-20AD XR) 
with auto-sampler and column oven connected to an AB Sciex API 5000 triple quadrupole mass 
spectrometer. The mobile phase conditions were as described previously (25). Ions were generated 
by positive electrospray ionisation. The ion transitions used for testosterone and internal standard 
were 289>97 and 292>109 respectively; and for androstenedione and internal standard were 287>97 
and 294>100 respectively. Androstenedione and internal standard eluted at 4.9 minutes. 
Testosterone and internal standard eluted at 5.2 minutes. The peak area for androstenedione or 
testosterone relative to the peak area for the internal standard was plotted against the concentration 
of the calibrators by the Analyst software. Calibrator ranges were 0.2-39.1 nmol/L for testosterone 
and 0.2-50 nmol/L for androstenedione. Results for quality control material and study samples were 
interpolated from the calibration lines. Inter-assay imprecision of androstenedione and testosterone 
in quality control material was shown in Supplementary table 2. 
 
SHBG measurement by immunoassay 
SHBG kits were obtained from Roche and the samples were run on an Elecsys 2010 analyzer (Roche 
Diagnostics GmbH. Two levels of quality control (QC) material were analyzed with each run on the 
analyzer and standard Westgard rules applied. The samples were analyzed blind and cases and 
controls were randomly mixed in batches using a single lot number of reagent and calibrator. One 
scientist did all the measurements. 
 
Calculation of free estradiol and testosterone  
For the calculation of free estradiol (fE2) and free testosterone (fT) the equation based on the law of 
mass action by Vermeulen was used (26). The equation relies on the assumption that the 
concentration of fE2 and fT in blood is determined mainly by interaction with SHBG and albumin, and 
that other hormones present in the blood exert little influence on this equilibrium. 
 
Statistical Analysis 
Mean and median levels of sex steroid hormones and SHBG were calculated for ER-positive and -
negative breast cancer cases and controls. Women were stratified into two groups based on whether 
their sample was obtained between 6 months and 2 years or between 2 and 5 years before breast 
cancer diagnosis, similar to Key et al (8). Differences in the medians between the groups were tested 
for statistical significance using the Mann-Whitney test. Subjects were classified according to quartiles 
of the respective marker among controls. The associations between hormone levels and the risk of 
breast cancer were determined by logistic regression analysis controlling for age.  
 
 
Results 
Cases included 202 women who developed ER-positive invasive breast cancer and 92 who developed 
ER-negative invasive breast cancer after joining UKCTOCS and 292 healthy controls. All reported no 
HRT use at recruitment. 6 were excluded from analysis as the assays failed in 3 women with ER-positive 
breast cancer and 5 controls. The median age of the 202 women with ER-positive breast cancer (cases) 
was 62 (IQR 9) and 62 (IQR 9) in the 200 healthy women (matched controls). The median age of the 
92 women with ER-negative breast cancer (cases) was 61 (IQR 9.25) and 60.5 (IQR 9) in the 92 healthy 
women (matched controls).  Breast tumour characteristics of the cases were similar to a typical breast 
cancer cohort – the majority of the ER-positive group were Stage 1 (39.5%), ductal (82.9%) and Grade 
2 (59.5%) and of the ER-negative group were Stage 1 (40.2%), ductal (98.9%) and Grade 3 (71.7%). 
Different lifestyle and anthropometric a characteristics are presented in Table 1 to provide the 
baseline information between cases and controls. Of the traditional risk factors investigated family 
history and body mass index were significantly different between cases and controls. (Table 1). Mean 
values were chosen as cut-points for continuous covariates in Table 1. 
Using all samples, correlations of sex steroid hormones and SHBG were investigated between ER-
positive and ER-negative groups. Among the ER-positive group, estradiol showed a statistically 
significant positive correlation with free estradiol, androstenedione, testosterone and free 
testosterone; testosterone showed a statistically significant positive correlation with free 
testosterone and androstenedione; and free testosterone showed a statistically significant positive 
correlation with androstenedione and a negative correlation with SHBG. Among the ER-negative 
group, estradiol showed a statistically significant positive correlation with free estradiol and 
androstenedione; androstenedione showed a statistically significant positive correlation with free 
estradiol, testosterone, free testosterone and a negative correlation with SHBG; and free testosterone 
showed a statistically significant positive correlation with testosterone and a negative correlation with 
SHBG (Supplementary table 3).  
For the ER-negative group, estradiol and free estradiol showed significant differences between cases 
and controls (Table 2). Women who provided their samples more than 2 years before cancer diagnosis 
had significantly higher levels of free estradiol compared to controls but women who provided their 
samples less than 2 years before cancer diagnosis did not show any significant differences (Table 2). 
For the ER-negative group as a whole, those with serum free estradiol level in the top quartile had 
2.52 (95 CI: 1.04-6.3, p=0.03) fold increased breast cancer risk. The association remained significant 
after adjustment for body mass index and family history (data not shown). However on subgroup 
analysis, the increased risk remained significant only in women who provided samples less than 2 
years before diagnosis (Table 3a). 
For the ER-positive group, the serum estradiol, free estradiol, free testosterone and SHBG showed 
significant differences between cases and controls (Table 2). Women who provided their samples less 
than 2 years before cancer diagnosis had significant higher levels of estradiol and free estradiol and 
lower of SHBG compared to controls. Women who provided their samples more than 2 years had 
significantly higher levels of estradiol, free estradiol and free testosterone and lower levels of SHBG 
compared to controls. For the ER-positive group, when all women were investigated, those with serum 
estradiol levels, free estradiol, free testosterone and SHGB in the top quartile had a 2.26 (95% CI: 1.28-
4.05, p=0.001), 2.77 (1.5-5.21, p=<0.001); 2.23 (95% CI: 1.23-4.1, p=0.004), 0.35 (95% CI: 0.19-0.64, 
p=0.001) breast cancer risk, respectively (Table 3b). Similar associations were observed on subgroup 
analysis based on whether their sample was obtained less than or more than 2 years before breast 
cancer diagnosis (Table 3b). All logistic regression analysis provided in Tables 3a and 3b were adjusted 
for age. No association was shown between breast cancer risk and androstenedione (Table 3b). 
Additionally, the association of the hormones with breast cancer risk remained significant after 
adjustment for body mass index and family history (data not shown). 
Discussion  
The current study adds to the ongoing effort to better understand the association of sex steroid 
hormones and breast cancer risk. This report is the first we are aware of that examines the role of sex 
steroid hormones measured using mass spectrometry for the androgens and an extraction RIA for 
estrogens in ER-positive and ER-negative breast cancers. Women had a fourfold increased ER-negative 
breast cancer risk if free estradiol was in the top quartile in the two years prior to diagnosis but not 
androgens or SHBG. Estradiol, free estradiol and free testosterone were significantly higher and SHBG 
significantly lower before ER-positive breast cancer diagnosis compared with controls. Women had a 
two fold increased ER-positive breast cancer risk if estradiol, free estradiol and free testosterone were 
in the top quartile and SHBG in the bottom quartile, with the association remaining significant 
regardless of whether the samples were collected less or over 2 years prior to diagnosis.  
The strengths of this study are the nested case control design within a large and well-characterized 
cohort of postmenopausal women with donation of serum samples prior to diagnosis. In keeping with 
previous reports, BMI (8) and family history were associated with ER-positive and negative breast 
cancer risk. Data on hormone receptor status was mainly from a breast cancer questionnaire sent to 
the treating physician. Endogenous estrogen and androgen were measured by the most accurate tests 
currently available to our laboratory - extraction RIA and mass spectrometry, respectively. Limitations 
include inability to stratify using tumour PR status because of small numbers and restricted 
generalizability of results to postmenopausal women using hormone therapy, non-white racial groups 
and premenopausal women. 
In ER-negative breast cancer, we found an association with serum estradiol and free estradiol but not 
with testosterone, free testosterone and androstenedione with women with higher levels of these 
hormones having increased risk. Currently there are 7 studies that have reported on the association 
of sex steroid hormone levels with breast cancer risk by receptor status (12-15, 17, 25, 26). Initial 
studies that investigated ER-negative breast cancers included only 20-45 women with little power to 
show any significant association (12, 15, 17, 27, 28). More recently there have been two larger studies 
by James et al (13), who investigated 172 ER-negative breast cancers and by Fharat et al (14), who 
investigated 111 ER-negatives breast cancers, which have shown conflicting results. The first study 
reported serum androgens (testosterone and free testosterone) and estrogens (estradiol and free 
estradiol) to be associated with increased risks of both ER-positive and ER-negative breast cancer. The 
latter study reported a significant reduction of breast cancer with increasing levels of testosterone 
and no association with estradiol. The current study, although itself of limited size, includes 
substantially more ER-negative cases of breast cancer than most previous studies. It needs to be noted 
though that the confidence intervals of the ORs are wide even though there is a trend for increased 
risk with increasing levels of the hormones, possibly due to the number of the cases investigated. 
All previous studies (12-15, 17, 27, 28) have generally shown an association between estrogen and/or 
androgens with ER-positive breast cancer type in postmenopausal women. Our study confirmed the 
association with estradiol, free estradiol and free testosterone but not androstenedione. This is in 
contrast to our previous findings in a separate group of 200 ER-positive women from the same cohort 
where there was a significant association of serum testosterone and androstenedione with increased 
breast cancer risk (9). These differences can only be explained by the fact that androgens were 
measured in this current study by mass spectrometry and in the previous by a direct immunoassay. It 
highlights the critical importance of assays used in postmenopausal women with low levels of 
circulating sex steroid hormones.  
Currently, the role of estrogens and androgens in tumour development is still controversial with 
conflicting data as to whether estrogens are responsible for the promotion of the early development 
of a breast tumour or the growth of an already established breast tumour at later stages (11). 
Furthermore, the fact that we show a significant association between estrogens and ER-negative 
breast cancer suggests that the estrogens exert their effects through different pathways other than 
through the ER. The role of androgens has been controversial in breast cancer and the mechanism of 
action still remains obscure. It is unclear as to whether they directly stimulate proliferation of breast 
cells or simply serve as estrogen precursors (15).  
In conclusion, this study provides evidence that in postmenopausal women higher levels of estradiol 
and free estradiol increase ER- negative and -positive breast cancer risk while higher levels of free 
testosterone increase ER- positive but not ER-negative. Androstenedione measured with mass 
spectrometry did not show significant association with either type of breast cancer. Further research 
is required to better understand the effect of the estrogens and androgens in breast tumour 
promotion and progression.  
 
Conflict of interest statement:  
Ian Jacobs has consultancy arrangements with Becton Dickinson, who have an interest in tumor 
markers and ovarian cancer. They have provided consulting fees, funds for research, and staff but not 
directly related to this study. Usha Menon has a financial interest through UCL Business and Abcodia 
Ltd in the third party exploitation of clinical trials bio-banks, which have been developed through the 
research at UCL. No other financial disclosures. 
 
Funding: 
UKCTOCS was core funded by MRC, Cancer Research UK and Department of Health with additional 
support from the Eve Appeal. This project was supported by a grant from the UCLH/UCL 
Comprehensive Biomedical Research Centre (CBRC) (project No 152) and most of the work has been 
undertaken at UCLH/UCL, which received a proportion of its funding from the Department of Health 
NIHR Biomedical Research Centers funding scheme. 
 
Acknowledgements:  
We are grateful to all UKCTOCS trialists, staff and especially participants who consented for use of 
their samples in secondary studies and the physicians who completed the breast cancer questionnaire.  
 
  
References 
1. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and 
prediction. Endocr Relat Cancer. 2010 Dec;17(4):R245-62. 
2. Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, et al. Critical 
assessment of new risk factors for breast cancer: considerations for development of an improved 
risk prediction model. Endocr Relat Cancer. 2007 Jun;14(2):169-87. 
 
3. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying 
taxonomy? Nature reviews Clinical oncology. 2009 Dec;6(12):718-30. 
 
4. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. 
Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer 
Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68. 
 
5. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005 May 14-
20;365(9472):1727-41. 
 
6. Collaborative Group on Hormonal Factors in Breast C. Menarche, menopause, and breast 
cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 
117 epidemiological studies. Lancet Oncol. 2012 Nov;13(11):1141-51. 
 
7. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. [Review]. 2000 
Mar;21(3):427-33. 
 
8. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in 
postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002 Apr 
17;94(8):606-16. 
 
9. Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, et al. Association of 
serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in 
postmenopausal women. Endocr Relat Cancer. 2012 Apr;19(2):137-47. 
 
10. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, et al. Postmenopausal serum 
androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer 
and nutrition. Endocr Relat Cancer. 2005 Dec;12(4):1071-82. 
 
11. Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE. Plasma sex 
hormone concentrations and subsequent risk of breast cancer among women using postmenopausal 
hormones. J Natl Cancer Inst. 2005 Apr 20;97(8):595-602. 
 
12. Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauleys JA. Sex hormones, risk factors, and 
risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. 
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1047-51. 
 
13. James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A, et al. Postmenopausal 
serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested 
case-control study. Cancer prevention research. 2011 Oct;4(10):1626-35. 
 
14. Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, et al. Sex hormone 
levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl 
Cancer Inst. 2011 Apr 6;103(7):562-70. 
 
15. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, et al. Sex hormone levels, breast 
cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer 
Epidemiol Biomarkers Prev. 2009 Jan;18(1):169-76. 
 
16. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, et al. 
Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a 
prospective study. Br J Cancer. 2004 Jan 12;90(1):153-9. 
 
17. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and 
progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer 
Inst. 2004 Dec 15;96(24):1856-65. 
 
18. Field HP. Tandem mass spectrometry in hormone measurement. Methods in molecular 
biology. 2013;1065:45-74. 
 
19.       Krasowski MD, Drees D, Morris CS, Maakestad J, Blau JL & Ekins S 2014 Cross-reactivity of 
steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity 
prediction. BMC Clin Pathol 14 33. 
 
20.        Stanczyk FZ, Lee JS & Santen RJ 2007 Standardization of steroid hormone assays: why, how, 
and when? Cancer Epidemiol Biomarkers Prev 16 1713-1719. 
 
21.      Dallal CM1, Tice JA, Buist DS, Bauer DC, Lacey JV Jr, Cauley JA, Hue TF, Lacroix A, Falk RT, Pfeiffer 
RM, Fuhrman BJ, Veenstra TD, Xu X, Brinton LA; B~FIT Research Group. Estrogen metabolism and 
breast cancer risk among postmenopausal women: a case-cohort study within B~FIT. Carcinogenesis. 
2014 Feb;35(2):346-55.  
 
22.       Fuhrman BJ1, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, Buys SS, Isaacs C, Keefer LK, 
Veenstra TD, Berg CD, Hoover RN, Ziegler RG. Estrogen metabolism and risk of breast cancer in 
postmenopausal women. J Natl Cancer Inst. 2012 Feb 22;104(4):326-39. 
23. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, et al. Recruitment to 
multicentre trials--lessons from UKCTOCS: descriptive study. Bmj. 2008;337:a2079. 
 
24. Fourkala EO, Gentry-Maharaj A, Burnell M, Ryan A, Manchanda R, Dawnay A, et al. 
Histological confirmation of breast cancer registration and self-reporting in England and Wales: a 
cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer. 2012 Jun 
5;106(12):1910-6. 
 
25. Barth JH, Field HP, Yasmin E, Balen AH. Defining hyperandrogenism in polycystic ovary 
syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem 
mass spectrometry and analysis by receiver operator characteristic plots. European journal of 
endocrinology / European Federation of Endocrine Societies. 2010 Mar;162(3):611-5. 
 
26. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the 
estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72. 
27. Zeleniuch-Jacquotte A, Toniolo P, Levitz M, Shore RE, Koenig KL, Banerjee S, et al. 
Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in 
postmenopausal women. Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):857-60. 
 
28. Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, et al. Circulating steroid 
hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers 
Prev.  Feb;19(2):492-502. 
 
 
  
Table 1 Risk factors for cases and controls in the ER POSITIVE and ER NEGATIVE groups 
 
 
 
 
Table 2 Characteristics of the hormones' values in different time groups 
  
ER POSITIVE ER NEGATIVE 
 
Category 
Case, 
N % 
Control, 
N % 
Total, 
N OR L95%CI U95%CI 
p-
value 
Case, 
N % 
Control, 
N % 
Total, 
N OR L95%CI U95%CI 
p-
value 
Ethnicity 
Non-
white 2 0.01% 7 0.04% 9 1 
   
1 0.01% 3 0.03% 4 1 
   
 
White 200 0.99% 193 0.97% 393 3.63 0.86 24.5 0.11 91 0.99% 89 0.97% 180 3.07 0.39 62.7 0.34 
Height <1.6 61 0.30% 65 0.33% 126 1 
   
35 0.38% 29 0.32% 64 1 
   
 
1.6+ 140 0.70% 134 0.67% 274 1.11 0.73 1.7 0.62 57 0.62% 63 0.69% 120 0.75 0.41 1.38 0.35 
BMI <24 52 0.26% 73 0.37% 125 1 
   
23 0.25% 45 0.49% 68 1 
   
 
24+ 149 0.74% 126 0.63% 275 1.66 1.09 2.55 0.02 69 0.75% 47 0.51% 116 2.87 1.55 5.43 0.001 
Age last period <50 85 0.42% 94 0.47% 179 1 
   
47 0.51% 47 0.51% 94 1 
   
 
50+ 117 0.58% 106 0.53% 223 1.22 0.82 1.81 0.32 45 0.49% 45 0.49% 90 1 0.56 1.78 1 
Age first period <12 34 0.17% 38 0.19% 72 1 
   
25 0.27% 15 0.16% 40 1 
   
 
12+ 166 0.83% 161 0.81% 327 1.15 0.69 1.93 0.59 67 0.73% 77 0.84% 144 0.52 0.25 1.06 0.08 
Pill use No 81 0.40% 85 0.43% 166 1 
   
40 0.44% 37 0.40% 77 1 
   
 
Yes 121 0.60% 115 0.58% 236 1.1 0.74 1.64 0.63 52 0.57% 55 0.60% 107 0.88 0.49 1.57 0.65 
Pregnancies <6Mth 0 139 0.70% 134 0.68% 273 1 
   
64 0.70% 64 0.70% 128 1 
   
 
1+ 61 0.31% 62 0.32% 123 0.95 0.62 1.45 0.81 28 0.30% 27 0.30% 55 1.04 0.55 1.96 0.91 
Pregnancies >6Mth 0 24 0.12% 13 0.07% 37 1 
   
10 0.11% 11 0.12% 21 1 
   
 
1+ 178 0.88% 186 0.94% 364 0.52 0.25 1.03 0.07 81 0.89% 81 0.88% 162 1.1 0.44 2.78 0.84 
Sterilization No 163 0.81% 147 0.74% 310 1 
   
75 0.82% 75 0.82% 150 1 
   
 
Yes 39 0.19% 53 0.27% 92 0.66 0.41 1.06 0.09 17 0.19% 17 0.19% 34 1 0.47 2.12 1 
Number of relatives 
breast 0 139 0.69% 155 0.78% 294 1 
   
63 0.69% 80 0.87% 143 1 
   
 
1+ 63 0.31% 45 0.23% 108 1.56 1 2.45 0.05 29 0.32% 12 0.13% 41 3.07 1.48 6.7 0.003 
Alcohol 0 41 0.20% 28 0.21% 69 1 
   
19 0.21% 16 0.18% 35 1 
   
 
1+ 160 0.80% 107 0.79% 267 1.02 0.59 1.75 0.94 73 0.79% 75 0.82% 148 0.82 0.39 1.72 0.6 
Smoker 0 115 0.57% 152 0.76% 267 1 
   
49 0.53% 59 0.64% 108 1 
   
 
1 87 0.43% 48 0.24% 135 2.4 1.57 3.69 <0.001 43 0.47% 33 0.36% 76 1.57 0.87 2.85 0.14 
Hysterectomy 0 170 0.84% 178 0.89% 348 1 
   
72 0.78% 80 0.87% 152 1 
   
 
1 32 0.16% 22 0.11% 54 1.52 0.86 2.76 0.16 20 0.22% 12 0.13% 32 1.85 0.86 4.15 0.12 
   ER POSITIVE 
  Controls Cases - All samples Cases - Less than 2 years before diagnosis Cases - More than 2 years before diagnosis 
  No Mean Median STD No Mean Median STD p-value No Mean Median STD p-value No Mean Median STD p-value 
Estradiol (pmol/l) 182 39.2 28 56.3 189 39.1 32 33.4 <0.01 93 40.1 32 42.8 0.02 96 38.1 32.5 20.8 0.01 
Free estradiol (pmol/l) 181 1.07 0.71 1.83 189 1.16 0.86 2.02 <0.01 93 1.27 0.86 2.8 0.01 96 1.05 0.85 0.65 <0.01 
Testosterone (nmol/l) 190 0.71 0.61 0.39 196 0.72 0.66 0.37 0.38 98 0.74 0.67 0.42 0.4 98 0.7 0.63 0.32 0.56 
Free testosterone 
(nmol/l) 190 0.008 0.007 0.006 196 0.009 0.008 0.006 0.01 98 0.009 0.008 0.005 0.04 98 0.01 0.008 0.007 0.06 
Androstenedione 
(nmol/L) 192 1.49 1.36 0.63 200 1.61 1.48 0.75 0.13 99 1.6 1.48 0.71 0.23 101 1.61 1.47 0.79 0.2 
SHBG (nmol/l) 200 68.9 64.4 29.6 202 59.9 54.5 26 <0.01 100 61.1 55.1 26.4 0.03 102 58.7 54.3 25.7 <0.01 
 
ER NEGATIVE  
  Controls Cases - All samples Cases - Less than 2 years before diagnosis Cases - More than 2 years before diagnosis 
  No Mean Median STD No Mean Median STD p-value No Mean Median STD p-value No Mean Median STD p-value 
Estradiol (pmol/l) 88 31.3 27 21.5 82 36.8 31 32.7 0.04 41 40.3 31 44.8 0.14 41 33.2 31 11.2 0.06 
Free estradiol (pmol/l) 88 0.84 0.72 0.77 82 1.09 0.82 1.78 0.03 41 1.29 0.82 2.49 0.13 41 0.88 0.82 0.33 0.04 
Testosterone (nmol/l) 85 0.52 0.49 0.33 90 0.56 0.46 0.41 0.89 47 0.55 0.45 0.49 0.72 43 0.56 0.53 0.32 0.54 
Free testosterone 
(nmol/l) 85 0.006 0.005 0.004 90 0.007 0.006 0.005 0.34 47 0.007 0.006 0.005 0.11 43 0.006 0.006 0.004 0.98 
Androstenedione 
(nmol/L) 90 1.21 1.15 0.54 92 1.22 1.16 0.58 0.89 49 1.2 1.15 0.62 0.72 43 1.23 1.22 0.53 0.87 
SHBG (nmol/l) 92 73.2 68.9 31.5 92 67.3 59.3 33.1 0.13 49 70 60.9 37.3 0.28 43 64.4 57.9 27.8 0.16 
 
  
Table 3a Quartile analysis in the ER NEGATIVE subgroup as a whole, and stratified by time to 
diagnosis 
 
    
All 
cases 
  
Cases 
- Less 
than 
2 
years 
  
Cases 
- 
More 
than 
2 
years 
 
 
Quartile Range 
N 
Controls 
N 
Cases OR N Controls 
N 
Cases  OR N Controls 
N 
Cases OR 
Estradiol (pmol/l) 1st 12-21.8 22 13 1 22 5 1 22 8 1 
 
2nd 21.8-27 23 16 1.18 (0.46-3.03) 23 9 1.72 (0.51-6.35) 23 7 0.84 (0.25-2.71) 
 
3rd 27-37 22 26 1.97 (0.82-4.91) 22 13 2.59 (0.81-9.31) 22 13 1.63 (0.57-4.86) 
 
4th 37-206 21 26 2.2 (0.9-5.57) 21 14 3.04 (0.96-11) 21 12 1.65 (0.56-5.07) 
     
P-value for trend= 
0.06 
  
P-value for trend= 
0.05 
  
P-value for trend= 
0.25 
Free Estradiol (pmol/l) 1st 0.29-0.54 22 12 1 22 4 1 22 8 1 
 
2nd 0.54-0.72 22 17 1.42 (0.55-3.71) 22 10 2.51 (0.72-10.3) 22 7 0.87 (0.26-2.85) 
 
3rd 0.72-0.94 22 22 1.86 (0.75-4.76) 22 12 3.07 (0.9-12.4) 22 10 1.29 (0.43-4.01) 
 
4th 0.94-7.34 22 30 2.52 (1.04-6.3) 22 15 3.76 (1.15-14.9) 22 15 1.86 (0.66-5.47) 
     
P-value for trend= 
0.03 
  
P-value for trend= 
0.04 
  
P-value for trend= 
0.17 
Androstenedione (nmol/l) 1st 0.21-0.84 23 27 1 23 12 1 23 15 1 
 
2nd 0.84-1.15 22 19 0.74 (0.32-1.69) 22 7 0.61 (0.19-1.82) 22 12 0.85 (0.32-2.21) 
 
3rd 1.15-1.57 22 21 0.83 (0.36-1.88) 22 12 1.17 (0.42-3.3) 22 9 0.59 (0.2-1.62) 
 
4th 1.57-2.64 23 24 0.865 (0.385-1.934) 23 12 1 (0.37-2.72) 23 12 0.76 (0.28-2.01) 
     
P-value for trend= 
0.82 
  
P-value for trend= 
0.79 
  
P-value for trend= 
0.54 
Testosterone (nmol/l) 1st 0.03-0.34 22 25 1 22 9 1 22 16 1 
 
2nd 0.34-0.49 21 22 0.93 (0.4-2.13) 21 12 1.43 (0.5-4.22) 21 10 0.65 (0.24-1.74) 
 
3rd 0.49-0.67 21 19 0.8 (0.34-1.86) 21 11 1.29 (0.44-3.86) 21 8 0.52 (0.18-1.44) 
 
4th 0.67-2.62 21 23 0.96 (0.42-2.2) 21 11 1.28 (0.44-3.78) 21 12 0.79 (0.3-2.05) 
     
P-value for trend= 
0.85 
  
P-value for trend= 
0.72 
  
P-value for trend= 
0.53 
Free Testosterone (nmol/l) 1st 0-0.004 22 24 1 22 8 1 22 16 1 
 
2nd 0.004-0.005 21 15 0.66 (0.27-1.59) 21 7 0.95 (0.28-3.156 21 8 0.5 (0.17-1.43) 
 
3rd 0.005-0.008 21 19 0.83 (0.35-1.94) 21 11 1.42 (0.48-4.36) 21 8 0.53 (0.18-1.46) 
 
4th 0.008-0.023 21 32 1.39 (0.63-3.12) 21 17 2.23 (0.81-6.54) 21 15 0.92 (0.36-2.35) 
     
P-value for trend= 
0.33 
  
P-value for trend= 
0.08 
  
P-value for trend= 
0.95 
SHBG (nmol/l) 1st 26-48.8 23 28 1 23 11 1 23 17 1 
 
2nd 48.8-68.9 23 28 0.99 (0.45-2.17) 23 16 1.55 (0.59-4.2) 23 12 0.71 (0.27-1.82) 
 
3rd 68.9-90.9 23 14 0.54 (0.22-1.3) 23 8 1.05 (0.32-3.48) 23 6 0.35 (0.11-1.01) 
 
4th 90.9-167 23 19 0.68 (0.29-1.54) 23 7 0.65 (0.2-1.94) 23 12 0.74 (0.28-1.91) 
     
P-value for trend= 
0.17 
  
P-value for trend= 
0.25 
  
P-value for trend= 
0.28 
 
 
